EudraVigilance is the EU system for collecting and analysing suspected adverse reaction reports, and EVDAS is the tool through which marketing authorisation holders (MAHs) can analyse that data. Having access is the easy part. Being able to show what you did with it is what inspectors test.
What access MAHs have
According to EMA, MAHs can access a defined set of data elements from individual case safety reports (ICSRs) for the medicines they hold an authorisation for in the European Economic Area. This covers spontaneous reports and reports from non-interventional studies. Senders can view all data elements of the cases they submitted themselves.
The access process runs through the EudraVigilance registration. The EU qualified person for pharmacovigilance, or a deputy, nominates the authorised staff. Access to case narratives needed for signal validation or other assessments requires a confidentiality undertaking. EMA has also published guidance on how MAHs should record information on the ICSRs they access.
What EVDAS is for
EVDAS, the EudraVigilance data analysis system, is the main access tool for MAHs and national authorities. It contains signal detection and data analysis functions, including reports that let a MAH review the reaction profile of its products over time and compare them with others in the same class.
Turning access into a process
- A defined routine: how often EudraVigilance data are reviewed for each product, by whom, and with what tools, written into the signal management procedure.
- Documented outcomes: each review leads to a record, including reviews that conclude there is nothing to act on.
- Connection to other sources: EVDAS findings should be read alongside the MAH’s own safety database, literature screening and aggregate reports.
- Escalation: clear criteria for when a finding becomes a validated signal and who notifies the authorities.
- Access control: a current list of authorised users, removal of leavers and training records.
Common weaknesses
Typical gaps are an undocumented review schedule, a reliance on a single person who holds the only login, and no link between EVDAS output and the PSUR or risk management plan. Another is forgetting that the data are a subset: EudraVigilance does not replace the MAH’s own database, and conclusions should say so.
The public face of the data
The same data are partly available to healthcare professionals, patients and academia through the public European database of suspected adverse drug reaction reports. Questions from journalists or prescribers often start there, so it is worth knowing what the public view shows for your products.
How PQRA helps
PQRA can help set up and document your EudraVigilance and EVDAS routine, draft the related sections of your signal management procedure, review user registration and access control, and prepare teams for inspection questions on how the system is used.
Contact PQRA to discuss your signal and EudraVigilance processes.


No responses yet